CA3095136A1 - Use of exosomes for targeted delivery of therapeutic agents - Google Patents
Use of exosomes for targeted delivery of therapeutic agents Download PDFInfo
- Publication number
- CA3095136A1 CA3095136A1 CA3095136A CA3095136A CA3095136A1 CA 3095136 A1 CA3095136 A1 CA 3095136A1 CA 3095136 A CA3095136 A CA 3095136A CA 3095136 A CA3095136 A CA 3095136A CA 3095136 A1 CA3095136 A1 CA 3095136A1
- Authority
- CA
- Canada
- Prior art keywords
- exosomes
- cancer
- protein
- disorder
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649057P | 2018-03-28 | 2018-03-28 | |
| US62/649,057 | 2018-03-28 | ||
| PCT/US2019/024603 WO2019191444A1 (en) | 2018-03-28 | 2019-03-28 | Use of exosomes for targeted delivery of therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3095136A1 true CA3095136A1 (en) | 2019-10-03 |
Family
ID=68060505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3095136A Pending CA3095136A1 (en) | 2018-03-28 | 2019-03-28 | Use of exosomes for targeted delivery of therapeutic agents |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3773747A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7813099B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200136978A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533643A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019243179B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3095136A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019191444A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| IT201900007785A1 (it) * | 2019-05-31 | 2020-12-01 | Univ Degli Studi Milano | Vescicole extracellulari per veicolare farmaci terapeutici o diagnostici |
| US20230013636A1 (en) * | 2019-12-05 | 2023-01-19 | Board Of Regents, The University Of Texas System | Exosomes-based therapy for liver fibrosis and other diseases with fibrosis |
| WO2021119552A1 (en) | 2019-12-13 | 2021-06-17 | Lawrence Livermore National Security, Llc | Nanotube-vesicle compositions and uses thereof |
| CN114081960A (zh) * | 2021-11-17 | 2022-02-25 | 中国人民解放军空军军医大学 | 一种前列腺癌分子靶向系统及其构建方法和应用 |
| CN114774471A (zh) * | 2022-05-10 | 2022-07-22 | 厦门星际诺康细胞科技有限公司 | 一种呈现il27稳转细胞及其构建方法、呈现il27工程化外泌体及其制备方法和应用 |
| KR20250171535A (ko) * | 2024-05-29 | 2025-12-09 | 사회복지법인 삼성생명공익재단 | 전기천공법을 이용한 상처치유용 세포외 소포체의 제조방법 |
| WO2026002276A1 (zh) * | 2024-06-28 | 2026-01-02 | 艾码生物科技(南京)有限公司 | 靶向tgfb的rna干扰方法、核酸及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
| US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
| GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
| EP3415627A1 (en) * | 2012-11-13 | 2018-12-19 | Codiak BioSciences, Inc. | Delivery of therapeutic agent |
| MX2015004626A (es) * | 2012-11-29 | 2015-07-14 | Yeda Res & Dev | Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis. |
| WO2015085096A1 (en) * | 2013-12-04 | 2015-06-11 | Board Of Regents, The University Of Texas System | Analysis of genomic dna, rna, and proteins in exosomes for diagnosis and theranosis |
| EA201890006A1 (ru) * | 2015-06-10 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Применение экзосом для лечения болезни |
| WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
| TWI601741B (zh) * | 2016-07-11 | 2017-10-11 | 財團法人國家衛生研究院 | 利用前列腺素受體ep4-拮抗劑誘導幹細胞製造含有高囊泡含物之外泌體囊泡的方法及其應用 |
-
2019
- 2019-03-28 CA CA3095136A patent/CA3095136A1/en active Pending
- 2019-03-28 KR KR1020207030993A patent/KR20200136978A/ko not_active Ceased
- 2019-03-28 EP EP19776678.5A patent/EP3773747A4/en active Pending
- 2019-03-28 JP JP2020551798A patent/JP7813099B2/ja active Active
- 2019-03-28 WO PCT/US2019/024603 patent/WO2019191444A1/en not_active Ceased
- 2019-03-28 AU AU2019243179A patent/AU2019243179B2/en active Active
- 2019-03-28 CN CN201980034058.9A patent/CN112533643A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021519296A (ja) | 2021-08-10 |
| CN112533643A (zh) | 2021-03-19 |
| EP3773747A4 (en) | 2022-02-23 |
| JP7813099B2 (ja) | 2026-02-12 |
| AU2019243179A1 (en) | 2020-11-12 |
| AU2019243179B2 (en) | 2025-09-18 |
| EP3773747A1 (en) | 2021-02-17 |
| WO2019191444A1 (en) | 2019-10-03 |
| KR20200136978A (ko) | 2020-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7620968B2 (ja) | 疾患の処置のためのエキソソームの使用 | |
| AU2019243179B2 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
| US20210369858A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
| AU2019255765B2 (en) | Therapeutic modulation of tumor suppressors using exosomes | |
| AU2018386215B2 (en) | Methods and compositions for treating cancer using exosomes-associated gene editing | |
| JP7599698B2 (ja) | エキソソームを用いたがん遺伝子に対する治療的な標的指向化の方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240328 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250103 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250103 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250103 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250320 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250325 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260325 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260331 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260511 |